We are live on ! Find out more
RCMNY

Rubric Capital Management (New York) Portfolio holdings

AUM $9.44B
1-Year Est. Return 68.42%
This Fund
S&P 500
This Quarter Est. Return
+6.02%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
–
AUM
$2.67B
AUM Growth
+$327M
Cap. Flow
+$290M
Cap. Flow %
10.89%
Top 10 Hldgs %
50.32%
Holding
72
New
10
Increased
21
Reduced
14
Closed
11

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$78.7M
2
RVNC
Revance Therapeutics, Inc.
RVNC
+$30.8M
3
NRG icon
NRG Energy
NRG
+$23.8M
4
QDEL icon
QuidelOrtho
QDEL
+$23.7M
5
HRTX icon
Heron Therapeutics
HRTX
+$21.3M

Top Sells

Rank Stock Value
1
VST icon
Vistra
VST
+$66.4M
2
HAPN
Happen Inc
HAPN
+$51.8M
3
STNG icon
Scorpio Tankers
STNG
+$48.8M
4
FLR icon
Fluor
FLR
+$34.7M
5
PARR icon
Par Pacific Holdings
PARR
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 35.61%
2 Energy 12.33%
3 Industrials 10.22%
4 Financials 7.91%
5 Utilities 6.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TAC icon
26
TransAlta
TAC
$3.91B
$38.3M 1.44%
4,404,844
+978,354
+29% +$9.5M
PLYA
27
DELISTED
Playa Hotels & Resorts
PLYA
$37.6M 1.41%
5,195,629
-2,012,667
-28% -$15.3M
CSTM icon
28
Constellium
CSTM
$4.03B
$35.6M 1.33%
1,954,274
-270,380
-12% -$4.77M
MGNI icon
29
Magnite
MGNI
$3.49B
$30.2M 1.13%
4,000,000
+1,785,978
+81% +$19.3M
HRTX icon
30
Heron Therapeutics
HRTX
$65.5M
$27.5M 1.03%
26,713,503
+14,963,503
+127% +$21.3M
ARQT icon
31
Arcutis Biotherapeutics
ARQT
$3.29B
$26.7M 1%
5,034,530
+150,000
+3% +$1.28M
IMVT icon
32
PUT
Immunovant
IMVT
$8.7B
$21.9M 0.82%
+569,800
New +$12.9M
QDEL icon
33
QuidelOrtho
QDEL
$1B
$21.7M 0.81%
+296,426
New +$23.7M
OVID icon
34
Ovid Therapeutics
OVID
$489M
$20.9M 0.78%
5,445,910
– –
VST icon
35
Vistra
VST
$49.1B
$20M 0.75%
602,189
-2,211,032
-79% -$66.4M
SCPH
36
DELISTED
scPharmaceuticals
SCPH
$19.3M 0.72%
2,713,287
+1,901,770
+234% +$15M
RVNC
37
DELISTED
Revance Therapeutics, Inc.
RVNC
$18.4M 0.69%
+1,600,000
New +$30.8M
AHCO icon
38
AdaptHealth
AHCO
$778M
$17.8M 0.67%
1,961,199
-917,940
-32% -$11M
AMRX icon
39
Amneal Pharmaceuticals
AMRX
$6.08B
$17M 0.64%
4,024,500
+1,423,121
+55% +$5.31M
ZYME icon
40
Zymeworks
ZYME
$1.77B
$16.8M 0.63%
2,651,394
+293,817
+12% +$2.17M
MREO
41
Mereo BioPharma
MREO
$47.7M
$15M 0.56%
11,616,120
– –
OABI icon
42
OmniAb
OABI
$494M
$14.8M 0.55%
2,850,588
+2,148,535
+306% +$11.5M
MSGS icon
43
Madison Square Garden
MSGS
$9.92B
$14.7M 0.55%
+83,512
New +$15.7M
PCRX icon
44
Pacira BioSciences
PCRX
$951M
$14.1M 0.53%
+459,637
New +$16.6M
TSAT icon
45
Telesat
TSAT
$916M
$13.7M 0.51%
959,764
-307,301
-24% -$4.18M
SSYS icon
46
Stratasys
SSYS
$771M
$12.4M 0.46%
+910,633
New +$14.4M
TRVI icon
47
Trevi Therapeutics
TRVI
$2.52B
$12.4M 0.46%
5,684,420
– –
STRO icon
48
Sutro Biopharma
STRO
$338M
$11.6M 0.44%
334,481
-70,393
-17% -$3.07M
CCO icon
49
Clear Channel Outdoor Holdings
CCO
$1.23B
$10.6M 0.4%
6,705,943
-10,685,484
-61% -$16.2M
FIP icon
50
FTAI Infrastructure
FIP
$552M
$10.3M 0.39%
3,193,530
– –
1
2
3

Similar funds

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return
LAMI
Longview Asset Management (Illinois) Chicago, Illinois $9.56B AUM 25.94% 1-Year Est. Return

Rubric Capital Management (New York)'s Q3 2023 Portfolio in Review

As of Q3 2023, Rubric Capital Management (New York) held 72 positions worth $2.67B, up 14% from $2.34B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Rubric Capital Management (New York) deployed $290M of net new capital in Q3 2023, opening 10 new positions and adding to 21 existing holdings. Its largest new stake was Revance Therapeutics, Inc.: 1,600,000 shares worth $18.4M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 33% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Vistra, an estimated $66.4M trimmed.

  • Rubric Capital Management (New York)'s largest Q3 2023 buy was Revance Therapeutics, Inc.: 1,600,000 shares worth $18.4M.
  • Rubric Capital Management (New York) added most to Roivant Sciences in Q3 2023, an estimated $78.7M increase.
  • Rubric Capital Management (New York)'s biggest Q3 2023 reduction was Vistra, cutting an estimated $66.4M.
  • Rubric Capital Management (New York) fully exited Happen Inc in Q3 2023, selling an estimated $51.8M.
  • Rubric Capital Management (New York)'s ten largest holdings make up 50% of its $2.67B portfolio in Q3 2023.
  • Rubric Capital Management (New York) opened 10 new positions and closed 11 in Q3 2023.
  • Rubric Capital Management (New York)'s portfolio value rose 14% quarter-over-quarter to $2.67B.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.